Replicate Biosciences
Biotechnology company pioneering self-amplifying RNA (saRNA) therapeutics, developing next-generation RNA medicines that can produce more protein from smaller doses compared to traditional mRNA.
Notes
Replicate Biosciences is a biotechnology company focused on developing self-amplifying RNA (saRNA) therapeutics. Unlike traditional mRNA, self-amplifying RNA contains additional genetic sequences that allow it to replicate within cells, producing more protein from smaller doses.
The company's saRNA platform offers potential advantages over conventional mRNA therapeutics, including lower dosing requirements, extended duration of protein expression, and potentially improved efficacy for certain applications including vaccines and protein replacement therapies.
Replicate Biosciences is part of the Apple Tree Partners portfolio.
Team
- Leadership team information not publicly available
Additional Research Findings
- Investor: Apple Tree Partners
- Self-amplifying RNA (saRNA) technology platform
- Potential for lower doses compared to mRNA
- Extended protein expression duration
- Applications in vaccines and therapeutics
- San Diego, California headquarters
Sources
- Apple Tree Partners Portfolio
- Company website
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apple Tree Partners | New York, USA | biotech-focused | series-aseries-b+2 | 23 |